Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Shema oral liquid** is an orally administered traditional Chinese medicine formula used for respiratory diseases, with reported antitussive, expectorant, and anti-asthmatic clinical effects. It is a multi-herb preparation containing Ephedra Herba, oxgall-processed Arisaematis Rhizoma, honey-roasted Morus alba bark, Belamcandae Rhizome, fried Raphani Semen, bitter apricot seed, Cynanchum glaucescens, Scutellariae Radix, vinegar-processed Schisandrae Chinensis Fructus, and Gypsum Fibrosum. In an LPS-induced COPD rat model, Shema improved ventilatory parameters, reduced pulmonary injury and circulating inflammatory cytokines, and reduced lung DNA methyltransferase 1 expression; this DNMT1-related mechanism remains preclinical rather than a clinically validated single-target mechanism. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9214040/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shema oral liquid.